News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
AOL.com Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Agenus is a clinical-stage immuno-oncology company focusing on its lead program, the BOT+BAL combination, for various solid tumors. The company is funding Phase 3 trials through an oversubscribed private placement in July 2026, aiming for commercialization and potential approvals. Despite strong recent stock performance …
The AI-driven nuclear power resurgence has been one of the hottest storylines over the past year. It has driven significant interest in nuclear energy stocks. Nuclear names like Oklo (NYSE: OKLO) and NuScale (NYSE: SMR) have been hot commodities as investors buy into the …
Renaissance Technologies LLC has reduced its stake in Agenus Inc. (NASDAQ:AGEN) by 47.4% in the first quarter, selling 257,900 shares and now owning 285,646 shares valued at approximately $954,000. Institutional investors collectively hold 61.46% of Agenus. Despite mixed analyst ratings, the biotechnology company's shares …
Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer at Supernus Pharmaceuticals, Inc., had 2,500 Performance Share Units (PSUs) vest on August 12, 2026. Following the vesting, 1,158 shares were withheld by the company at $46.57 per share to cover tax …
Supernus Pharmaceuticals' Chief Medical Officer, Jonathan Rubin, exercised 750 Performance Share Units (PSUs) on August 12, 2026, converting them into 750 shares of common stock. To cover tax withholding requirements associated with this vesting, 363 shares were withheld by the company at a price …
Van Eck Associates Corporation has disclosed an 8.5% beneficial ownership stake in NuScale Power Corp Class A ordinary shares, totaling 29,311,762 shares, through an amendment to its SCHEDULE 13G filing. The firm holds sole voting and dispositive power over these shares. A significant portion, …
Key Points By mid-2009, utilities had filed applications for 26 new U.S. reactors; only Vogtle Units 3 and 4 were ever completed. Vogtle's two units were originally estimated at $14 billion and ended up costing more than $30 billion, entering service about seven years …
KeyBanc analysts have issued bullish ratings for several industrial goods companies. Michael Leshock maintained a Buy rating on Firefly Aerospace, Inc. (FLY) with a Strong Buy consensus. Jeffrey Hammond reiterated a Buy rating on Janus International Group (JBI), while Sangita Jain maintained a Buy …
NuScale (NYSE: SMR) could become a foundational company in the next nuclear era. Its advantage is not an exotic breakthrough, but a practical reactor built around proven technology, conventional fuel, and repeatable manufacturing. The upside could be enormous if it converts regulatory progress into …
Assenagon Asset Management S.A. significantly reduced its stake in Supernus Pharmaceuticals (NASDAQ:SUPN) by 86.2% in the second quarter, selling 457,443 shares and retaining 73,175 shares valued at $3.4 million. Despite this large sale, analyst sentiment for Supernus remains generally positive, with a "Moderate Buy" …
Agenus Inc. has granted its Chairman and CEO, Armen Garo H, 1.97 million performance-tied stock options with an exercise price of $7.78 per share, expiring in 2036. The options are divided into five equal tranches, each vesting only if the company's stock price reaches …
NuScale Power (SMR) has announced an At-The-Market (ATM) equity offering program to sell up to $750 million in Class A common stock. This program provides the company with a flexible method to raise capital, which can be used to strengthen its balance sheet and …
Indivior Pharmaceuticals (NasdaqGS: INDV) has agreed to merge with Supernus Pharmaceuticals, forming a new entity named Supernus, Inc., with shared leadership. This merger is expected to significantly reshape both companies' corporate governance and operations, especially concerning Indivior's buprenorphine-based treatments. Investors should watch the combined …
NuScale Power Corporation SMR is approaching a potentially important commercial inflection point as ENTRA1 Energy advances discussions with the Tennessee Valley Authority toward definitive power purchase agreements. However, the stock has lost more than 75% over the past year, underscoring how much investor sentiment …
NuScale Power Corporation SMR has a credible path toward commercializing its small modular reactor technology, supported by U.S. regulatory approval, supplier readiness and ample liquidity. The opportunity is substantial, but so are the expectations embedded in the stock. The key question is whether that …
Agenus Inc. (Nasdaq: AGEN) will present three-year survival data from its Phase 1b C-800-01 study of botensilimab (BOT) and balstilimab (BAL) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the ESMO Gastrointestinal Cancers Congress 2026. The presentation will include updated findings and longer-term …
Oklo Inc. OKLO crossed an important threshold in the second quarter of 2026 by reporting revenues for the first time, showing that its advanced nuclear strategy is beginning to produce commercial activity. The milestone came alongside operational progress, including criticality at the Groves isotope …
Janus International Group has released its Q2 2026 financial results and updated investor presentations. The company submitted a current report to the SEC detailing its performance for the quarter ending July 4, 2026, including an earnings presentation and a refreshed investor presentation. These materials, …
Search by ticker symbol or company name and select a result to open its chart.